<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04876092</url>
  </required_header>
  <id_info>
    <org_study_id>CR109010</org_study_id>
    <secondary_id>2021-000191-12</secondary_id>
    <secondary_id>67856633LYM1002</secondary_id>
    <nct_id>NCT04876092</nct_id>
  </id_info>
  <brief_title>A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL</brief_title>
  <official_title>A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and recommended Phase 2 dose (RP2D) of&#xD;
      JNJ-67856633 and ibrutinib in combination in participants with B cell non-Hodgkin lymphoma&#xD;
      (NHL) and chronic lymphocytic leukemia (CLL) in Part A (Dose Escalation) and to evaluate&#xD;
      safety of JNJ-67856633 and ibrutinib in combination, at the RP2D regimen in Part B (Cohort&#xD;
      Expansion).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-Hodgkin lymphoma (NHL) represents the most frequent hematologic malignancy in the world&#xD;
      and represents a diverse set of diseases. JNJ-67856633-ZAF (referred as JNJ-67856633) is an&#xD;
      orally bioavailable, potent, and selective first-in-class mucosa-associated lymphoid tissue&#xD;
      lymphoma translocation protein-1 (MALT1) inhibitor. JNJ-67856633 binds to an allosteric site&#xD;
      on MALT1 with a mixed-type mechanism. Ibrutinib is a first-in-class, orally administered,&#xD;
      potent, orally administered covalently binding small-molecule inhibitor of Bruton's tyrosine&#xD;
      kinase (BTK), as well as interleukin-2-inducible kinase (ITK), a tyrosine protein (Tec)&#xD;
      kinase family member present in T cells. The study will be conducted in 2 parts: Part A (Dose&#xD;
      Escalation) and Part B (Expansion Phase). In dose escalation phase, one or more recommended&#xD;
      Phase 2 dose (RP2Ds) of JNJ-67856633 will be determined. After the RP2D(s) is determined in&#xD;
      the dose escalation phase, expansion phase will be conducted. The study is divided into 3&#xD;
      periods: a screening phase, a treatment phase, and a post-treatment follow-up phase. Efficacy&#xD;
      assessments will include radiographic image assessments, positron emission tomography scan,&#xD;
      bone marrow assessment, endoscopy etc. Safety assessment like physical examination, vital&#xD;
      signs, electrocardiogram (ECG), eastern cooperative oncology group (ECOG) performance status,&#xD;
      and adverse events monitoring will be performed during the study. Total duration of the study&#xD;
      will be up to 2 years and 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">December 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Percentage of Participants with DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematological toxicity or hematological toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) by Severity</measure>
    <time_frame>Up to 2 years and 6 months</time_frame>
    <description>Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Plasma Concentration of JNJ-67856633 and Ibrutinib</measure>
    <time_frame>Up to 2 years and 6 months</time_frame>
    <description>Plasma samples will be analyzed to determine concentrations of JNJ-67856633 and Ibrutinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Duration of Response (DOR)</measure>
    <time_frame>Up to 2 years and 6 months</time_frame>
    <description>DOR is defined for participants who achieved PR, MaRR or CR as the time between the date of initial documentation of such responses to the date of either the first documented evidence of relapse or death. For participants who have not relapsed or died, data will be censored at the last disease evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Time to First Response (TTR)</measure>
    <time_frame>Up to 2 years and 6 months</time_frame>
    <description>TTR is defined for participants who achieved PR, MaRR, or CR as the time from the first dose of study drug to first of such responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Overall Response Rate (ORR)</measure>
    <time_frame>Up to 2 years and 6 months</time_frame>
    <description>ORR is defined as the percentage of participants who have a partial response (PR) and complete response (CR) according to Non-Hodgkin Lymphoma (NHL), International Workshop on Chronic Lymphocytic Leukemia (iwCLL) and Waldenstrom macroglobulinemia (WM) response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Complete Response Rate</measure>
    <time_frame>Up to 2 years and 6 months</time_frame>
    <description>Complete response rate is defined as the percentage of participants who achieve a best response of CR according to the iwCLL, NHL and WM response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Major Response Rate (MaRR)</measure>
    <time_frame>Up to 2 years and 6 months</time_frame>
    <description>MaRR (PR+ very good partial response [VGPR]) rate is defined as the percentage of participants who achieve a best response of PR or VGPR according to NHL, iwCLL and WM response criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>JNJ-67856633 and Ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part A (dose escalation) will receive JNJ-67856633 together with Ibrutinib orally on a 21-day cycle. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Doses (RP2Ds) has been identified. Participants in Part B (cohort expansion) will receive JNJ-67856633 together with Ibrutinib orally at one of the RP2D(s) determined in Part A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-67856633</intervention_name>
    <description>Participants will receive JNJ-67856633 orally.</description>
    <arm_group_label>JNJ-67856633 and Ibrutinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Participants will receive Ibrutinib orally.</description>
    <arm_group_label>JNJ-67856633 and Ibrutinib</arm_group_label>
    <other_name>JNJ-54179060</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1&#xD;
&#xD;
          -  Cardiac parameters within the specified range&#xD;
&#xD;
          -  Women of childbearing potential must agree to all of the following during the study&#xD;
             and for 3 months after the last dose of study drug: a) use a barrier method of&#xD;
             contraception; b) use a highly effective contraceptive methods; c) not to donate eggs&#xD;
             (ova, oocytes) or freeze them for future use for the purposes of assisted reproduction&#xD;
             during the study; d) not to plan to become pregnant; e) not to breast-feed&#xD;
&#xD;
          -  Willing and able to adhere to the lifestyle restrictions specified in this protocol&#xD;
&#xD;
          -  Participants must have tumor tissue availability&#xD;
&#xD;
          -  Adequate organ functions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known (active) Central Nervous System (CNS) involvement&#xD;
&#xD;
          -  Prior treatment with JNJ-67856633 or another MALT1 inhibitor that is associated with&#xD;
             disease progression or intolerable toxicities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes hôtel-Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital St Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alexandra General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Jeollanam-do</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Yeouido St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07345</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Krakow</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Poznan</name>
      <address>
        <city>Skorzewo</city>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>S.P. Botkin Moscow City Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nizhniy Novgorod Region Clinical Hospital</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncological dispensary #2</name>
      <address>
        <city>Sochi</city>
        <zip>354057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St.-Petersburg Clinical Research Institute of Hematology and Transfusiology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Germans Trias I Pujol</name>
      <address>
        <city>Badalona, Barcelona</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset Lund, Onkologiska Kliniken, Lund</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR109010</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

